ATLANTA, June 20, 2024 (GLOBE NEWSWIRE) -- Femasys, Inc., (NASDAQ:FEMY), a leading biomedical company focused on addressing significant unmet needs of women worldwide with a broad portfolio of inoffice, accessible, and innovative therapeutic and diagnostic products, announces it has received its European Union Medical Device Regulation (EU MDR) certificate and CE Mark certification for four of its products. The four products – FemaSeed®, FemVue®, FemCerv®, and FemCath® – are compliant with the new European ...

Femasys is an Atlanta-based company that provides minimally invasive women's reproductive health solutions, which are manufactured in the U.S. Later this week, the Company will be displaying its four commercially available products: FemaSeed® – FDA-cleared, intratubal insemination; FemVue® – contrast-generating device; FemCath® – selective delivery catheter; FemCerv® – endocervical tissue sampler; and its current lead product candidate in late-stage clinical development FemBloc® – a non-surgical, non-hormon ...

ATLANTA, May 17, 2024 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical company focused on addressing significant unmet needs of women worldwide with a broad portfolio of inoffice, accessible, and innovative therapeutic and diagnostic products, announces CEO and Founder Kathy LeeSepsick has met with staff from the White House Office of Science and Technology Policy (OSTP) to discuss the President and First Lady's Cancer Moonshot and the Company's FemCerv® product. According to The White ...

ATLANTA, May 16, 2024 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ:FEMY), a leading biomedical company focused on addressing significant unmet needs of women worldwide with a broad portfolio of inoffice, accessible, and innovative therapeutic and diagnostic products, announces CEO and Founder Kathy LeeSepsick met with the White House's Gender Policy Council (GPC) staff to discuss the Company's reproductive health products and the future of women's health in the United States. According to The White House, "The ...

ATLANTA, May 16, 2024 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical company focused on addressing significant unmet needs of women worldwide with a broad portfolio of inoffice, accessible, and innovative therapeutic and diagnostic products, announces CEO and Founder Kathy LeeSepsick met with the White House's Gender Policy Council (GPC) staff to discuss the Company's reproductive health products and the future of women's health in the United States. According to The White House, "The ...

Femasys Inc. (FEMY) came out with a quarterly loss of $0.17 per share versus the Zacks Consensus Estimate of a loss of $0.22. This compares to loss of $0.25 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 22.73%. A quarter ago, it was expected that this company would post a loss of $0.19 per share when it actually produced a loss of $0.19, delivering no surprise.Over the last four quarters, the company has surpassed consensus ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 Suwanee, GA 30024 (Address of principal executive offices) (Zip Code) (770) 500-3910 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ____________to____________ Commission file number: 001-40492 Femasys Inc. ...

Exhibit 99.1 • Company announced positive topline data from pivotal trial for FDA-cleared FemaSeed® for the treatment of infertility. • Company announced the first in-office commercial procedure with FDA-cleared FemaSeed infertility solution at a former investigative site. • Appointed Richard Spector as Chief Commercial Officer. • Initiated enrollment in pivotal trial (NCT05977751) of our permanent birth control candidate FemBloc at two academic sites, for a total of six active sites, the maximum permitted ...

-- Recruitment of the commercial team for our infertility portfolio and the pivotal trial of FemBloc® for permanent non-surgical birth control continues -- ATLANTA, May 09, 2024 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ:FEMY), a leading biomedical company focused on addressing significant unmet needs of women worldwide with a broad portfolio of in-office, accessible and innovative therapeutic and diagnostic products, announces financial results for the quarter ended March 31, 2024 and provides a corporate up ...

ATLANTA, May 07, 2024 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ:FEMY), a leading biomedical company focused on addressing significant unmet needs of women worldwide with a broad portfolio of in-office, accessible, and innovative therapeutic and diagnostic products, today announces the expansion of its commercial management team, marking a significant milestone in the company's mission to advance women's health worldwide. With the addition of new team members to its commercial team in key strategic geographic ...